Oxford Biomedica agreed to acquire French CDMO ABL Europe, a subsidiary of Institut Mérieux, for 15 million euros ($16 million) in a deal that will give the drugmaker expanded viral vector ...
Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe The transaction Provides Oxford Biomedica with multi viral vector CDMO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results